Your browser doesn't support javascript.
loading
Valve-in-valve transcatheter mitral valve replacement versus redo-surgical mitral valve replacement for degenerated bioprosthetic mitral valves: A systematic review and meta-analysis.
Nasir, Muhammad Moiz; Amir, Suhaina; Shahid, Ahmad; Rehman, Wajeeh Ur; Haris, Muhammad; Ikram, Armeen; Mubariz, Muhammad; Ahmed, Jawad; Khan, Ubaid; Iqbal, Abdul Ghani; Saeed, Hasham; Noori, Muhammad Atif Masood.
Afiliación
  • Nasir MM; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Amir S; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Shahid A; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Rehman WU; Department of Internal Medicine, United Health Services Hospital, Johnson City, NY, USA.
  • Haris M; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan. Electronic address: harisjalal2.0@gmail.com.
  • Ikram A; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Mubariz M; Department of Internal Medicine, Akhtar Saeed Medical and Dental College, Lahore, Pakistan.
  • Ahmed J; Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Khan U; Division of Cardiovascular Medicine, University of Maryland, School of Medicine, Baltimore, MD, USA.
  • Iqbal AG; Department of Internal Medicine, UNC Nash General Hospital, NC, USA.
  • Saeed H; RWJBarnabas Health/Trinitas Regional Medical Center, NJ, USA.
  • Noori MAM; Department of Cardiovascular Medicine, St Joseph's University Medical Center, Paterson, NJ, USA.
Int J Cardiol ; 415: 132448, 2024 Nov 15.
Article en En | MEDLINE | ID: mdl-39153510
ABSTRACT
Bioprosthetic mitral valve degeneration is traditionally treated with Redo-SMVR, but the latest ViV-TMVR procedure offers a less invasive and lower risk alternative. A systematic literature search was conducted on Cochrane Central, Scopus, and Medline (PubMed interface) electronic databases from inception till 15th April 2024. We used risk ratios (RR) for dichotomous outcomes and mean differences (MD) for continuous outcomes. We included a total of eleven studies with 11,931 patients in the final quantitative and qualitative analysis. When comparing ViV-TMVR with Redo-SMVR, no significant difference was found for 30-day mortality (P = 0.13) and 1-year mortality (P = 0.91), whereas patients in the ViV-TMVR showed significantly reduced incidence of stroke (P < 0.00001), In-hospital mortality (P), bleeding complications (P = 0.003), AKI (P = 0.0006), arrhythmias (P = 0.01), LVOT obstruction (P = 0.04), and PPI (P < 0.00001). Furthermore, no significant difference was observed between either group when comparing vascular complications (P = 0.97), 2-year mortality (P = 0.60) and 3-year mortality. ViV-TMVR was associated with a significant risk of paravalvular leakage (P = 0.008). Although, ViV-TMVR reduces the risk of complications associated with Redo-SMVR, larger studies are imperative to reach conclusive results.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reoperación / Bioprótesis / Falla de Prótesis / Prótesis Valvulares Cardíacas / Implantación de Prótesis de Válvulas Cardíacas / Válvula Mitral Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reoperación / Bioprótesis / Falla de Prótesis / Prótesis Valvulares Cardíacas / Implantación de Prótesis de Válvulas Cardíacas / Válvula Mitral Límite: Humans Idioma: En Revista: Int J Cardiol Año: 2024 Tipo del documento: Article País de afiliación: Pakistán Pais de publicación: Países Bajos